SCHEMBL14731908

SCHEMBL14731908

CCN[C@H](C)CCc1ccc(O)c(OC)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.72
ATM Q13315 1/20 0.72
TMEM97 Q5BJF2 3/20 0.66
ADRB2 P07550 3/20 0.57
HTR1A P08908 1/20 0.56
TAAR1 Q96RJ0 2/20 0.56
TSHR P16473 2/20 0.56
MAPK1 P28482 2/20 0.56
SIGMAR1 Q99720 3/20 0.55
LMNA P02545 2/20 0.55
FOS P01100 1/20 0.55
TTR P02766 1/20 0.55
JUN P05412 1/20 0.55
NR3C1 P04150 1/20 0.55
HSD17B1 P14061 1/20 0.55
HSD17B2 P37059 1/20 0.55
GLA P06280 1/20 0.55
PTPN1 P18031 1/20 0.54
ALOX5 P09917 1/20 0.54
OR51E2 Q9H255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31545704 0.85 FOS (0.67) GAAATMTMEM97TAAR1TSHR
SCHEMBL19117433 0.85 GAA (0.67) GAAATMTMEM97ADRB2HTR1A
SCHEMBL16364799 0.85 GAA (0.67) GAAATMTMEM97ADRB2HTR1A
SCHEMBL14731749 0.84 GAA (0.81) GAAATMTMEM97ADRB2HTR1A
SCHEMBL14731883 0.84 GAA (1.00) GAAATMTMEM97ADRB2TAAR1
SCHEMBL16774021 0.83 GAA (0.80) GAAATMTMEM97ADRB2HTR1A
SCHEMBL14731802 0.83 GAA (0.80) GAAATMTMEM97ADRB2HTR1A
SCHEMBL14731737 0.83 GAA (0.80) GAAATMTMEM97ADRB2HTR1A
SCHEMBL14731840 0.83 GAA (0.80) GAAATMTMEM97ADRB2HTR1A
SCHEMBL582113 0.83 GAA (0.80) GAAATMTMEM97ADRB2TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378460-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2014-12-25 US disclosed
WO-2013029060-A2 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2013-02-28 WO disclosed
WO-2013029057-A2 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378460-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, SIGMAR1 GAA 1564/4885ATM 4274/4885TMEM97 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.